Clinical Trial

A new drug targeting cancer's 'immortality switch' enters a pivotal trial, offering hope for non-small cell lung cancer patients out of options.

A novel drug for muscle loss in COPD patients has fully recruited its Phase 2 trial, a major step towards the first-ever treatment for sarcopenia.

A new drug combination delays cancer progression by over a year in advanced prostate cancer, offering new hope against treatment resistance, a new study finds.

New long-term data on pegcetacoplan offers significant hope for patients with rare, debilitating kidney diseases, strengthening Sobi's market position.

With strong data for volixibat, brelovitug, and LIVMARLI, Mirum (MIRM) de-risks its pipeline and sets the stage for growth. Here's the analysis.

A novel drug aims to starve deadly brain tumors by rewiring their metabolism. BPGbio's upcoming ASCO update could signal a major shift for glioblastoma.

PeproMene Bio’s PMB-CT01 offers new hope, achieving a 78% complete response rate with a remarkable safety profile in hard-to-treat lymphoma patients.

BeOne Medicines' immunotherapy TEVIMBRA gains key reimbursement nods, paving the way for Canada's first funded option for a rare head and neck cancer.

A new clinical trial is testing a therapy that treats donor kidneys before transplant, aiming to prevent a common virus that complicates 30% of cases.

Groundbreaking research on new drug classes, the gut-brain axis, and personalized medicine will be unveiled at the upcoming American Headache Society meeting.

Therini Bio's novel drug THN391 enters trials, targeting inflammation in diabetic eye disease, while a next-gen combo therapy aims to redefine care.

A new partnership between biotech leader Debut and Amazonian expert Natura aims to revolutionize anti-aging skincare with AI-discovered ingredients.

NEOK Bio begins Phase 1 trials for two bispecific ADCs, a next-gen therapy aiming to outsmart tumor resistance and offer new hope for solid tumor patients.

New preclinical data shows RTY-406 could be a first-in-class therapy for PSC, a progressive liver disease with no effective treatments.

Vanda Pharmaceuticals' rare disease drug gets a key designation in Japan, unlocking major incentives and promising a new treatment for a severe skin disease.

With CHF 105 million in new funding, NUCLIDIUM is advancing its novel copper-based radiotheranostics for metastatic prostate and breast cancer.

Positive Phase 3 data for oral drug filgotinib offers new hope for thousands of axial spondyloarthritis patients who fail to respond to current therapies.

John Theurer Cancer Center presents breakthroughs in CAR-T, ADCs, and health equity at ASCO, offering new hope for patients worldwide.

A new global repository by Zifo and the Pistoia Alliance aims to standardize biological data, promising to accelerate drug discovery and fix costly data silos.

MBX Biosciences prepares for the Jefferies conference, with investors eyeing updates on its late-stage hypoparathyroidism drug and promising obesity portfolio.